Early Detection of Complications During Immunotherapy for Haematological Malignancy
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorRigshospitalet, Denmark
About this trial
Aims
* To identify patients that should remain admitted in hospital for more intense surveillance because of high risk for development of clinical complications * Expand the understanding of the interactions between physiology and immunology for the design of future projects and general knowledge Hypothesis Development of a risk model based on a combination of physiological and immunological parameters can contribute to early detection of patients at risk for clinical complications after anti-cancer treatment.
Eligibility criteria
Qualifiers
Age ≥ 18 years
Patients diagnosed with haematologic malignant disease (e.g. malignant lymphoma)
Patients scheduled for treatment with CART or BsAbs
Disqualifiers
Patient is pregnant
Patient has a pacemaker
Patient is allergic to one or more of the materials that the equipment consists of
Investigator deems patient not able to comply with participation in the study
Trial design
Treatments tested in this trial
- WARD
Treatment groups
100 Participants
are divided into 1 treatment groupLocations
1Map coordinates are unavailable for these locations. Locations are shown below instead.
RigshospitaletRecruiting2100, Copenhagen O
Denmark
DenmarkSponsors and collaborators
Source ClinicalTrials.gov